Alliance Pharma plc (LON:APH) has announced that the Medicines and Healthcare products Regulatory Agency (MHRA) has approved the UK Marketing Authorisation Application for Diclectin, a prescription product for the treatment of nausea and vomiting of pregnancy.
The AIM-listed pharmaceutical company also said that the MHRA has approved the brand name Xonvea, which will be used for marketing Dicelctin in the UK.
The company said it anticipates Xonvea’s launch in autumn this year as the only medicine licensed in the UK for the treatment of nausea and vomiting during pregnancy.
Alliance Pharma estimates peak sales for Xonvea in the UK of approximately £10mln and £30mln across the other nine European countries at peak sales.
Peter Butterfield, Alliance Pharma's chief executive officer, said: "There are currently no licensed treatments for nausea and vomiting of pregnancy in the UK so this is excellent news for patients and clinicians as it fulfils a significant unmet medical need."